The SVR name is already taken—see #msg-77005615. GILD thinks of everything :- )
Interesting, didn't know that. I kind of like ACHN's name better as sovaprevir rolls off the tongue a little easier than sofosbuvir IMO.
Separately, more color on ACHN @ JMP, at the tail end of the presentation during Q&A there is some discussion on elevated liver enzymes reported at EASL on the Phase 2a sovaprevir data. Sounds like at 800mg QD there were 2 increases in bilirubin that were most likely attributable to sovaprevir. Also, I think it was mentioned that there were also 2 patients in 400mg QD dose and 2 patients in 800mg QD dose that had elevations in ALT that were transient and returned to baseline while the patients were still on treatment. You see any reason for potential concern for sovaprevir given these disclosures?
Market Data 
Markets 
AI
